CN Bio logoCN Bio logoCN Bio logoCN Bio logo
  • Products
    • Explore our solutions


      PhysioMimix™ products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Multi-organ models

      Support packages

      • PhysioMimix™ support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix™ products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • Oncology
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

      Oncology icon

      Oncology

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system

      • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place.

      • CN Bio appoints Dr Paul Brooks as Chief Executive Officer

      View all news

      Upcoming Events

      • SLAS2023

      • SOT 2023

      • WORD 2023

      • SLAS Europe 2023

      • MPS World Summit 2023

      View all events

      Join the team!

      View all jobs
  • Contact
  • Products
    • PhysioMimix™ OOC Microphysiological Systems
    • Consumables
      • PhysioMimix™ multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

Safety toxicology

Human-relevant in vitro safety toxicology models better predict adverse drug effects to reduce risk in the clinic

Current industry methods

Simple cell culture systems lack physiological complexity and animal models are poor predictors of drug safety in humans. This limits the extrapolation of data from these systems to human safety toxicology.

Many drugs with clean preclinical toxicity profiles will produce adverse effects in human trials leading to costly late-stage withdrawals and potential harm to study participants. Conversely, false positive results may cause the termination of potential blockbusters unnecessarily.

Advancements with PhysioMimix™

PhysioMimix organ-on-a-chip models recreate in vivo physiology and function in vitro. They provide a human-specific understanding of potential drug toxicity in healthy and diseased organ models.

Data derived from these models complement data from more traditional approaches to flag potential side effects and allow these to be addressed early in the drug discovery pipeline.

LC12 multi-organ plate

Drug-induced liver injury


Adverse drug reactions are a major clinical problem, and the liver is one of the most susceptible organs to drug toxicity.

Our drug-induced liver injury (DILI) assay can assess the toxicity of a wide range of entities (small molecules, protein, ASOs, AAVs, etc) in the presence or absence of liver disease.

It facilitates more informed predictions of human liver responses to acute and chronic drug exposure using a broad spectrum of clinically translatable endpoints.

Learn more
Plate examined in lab

Immune-mediated toxicities


Predicting immune-mediated, or idiosyncratic toxicity is challenging because of the complexity of the immune system, limited understanding of the underlying mechanisms, and a lack of suitable models.

Our immunocompetent organ-on-a-chip models can provide data on the reaction mechanisms that determine how inflammation influences drug-induced toxicity.

Learn more

Jump to area of interest

Drug-induced liver injury
Immune-mediated toxicities

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

+44 (0) 1223 737941

Privacy | Cookies | Terms | Regulatory | Accessibility

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. 978184563

Latest news

  • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system January 17, 2023
  • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place. January 9, 2023
  • CN Bio appoints Dr Paul Brooks as Chief Executive Officer December 19, 2022

Upcoming events

MPS World Summit 2023 June 26-30, 2023

SLAS Europe 2023 May 22-26, 2023

SLAS2023 February 25 - March 1, 2023